Repositioning Candidate Details
| Candidate ID: | R0922 |
| Source ID: | DB06082 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | PX-478 |
| Synonyms: | -- |
| Molecular Formula: | C13H20Cl4N2O3 |
| SMILES: | Cl.Cl.N[C@@H](CC1=CC=C(C=C1)[N+]([O-])(CCCl)CCCl)C(O)=O |
| Structure: |
|
| DrugBank Description: | PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha. |
| CAS Number: | 685898-44-6 |
| Molecular Weight: | 394.11 |
| DrugBank Indication: | Investigated for use/treatment in cancer/tumors (unspecified). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | PX-478 is a novel small molecule compound that inhibits the activity of hypoxia inducible factor (HIF)-1 alpha, a transcription factor that controls the expression of a number of genes important for growth and survival of cancer cells. Genes regulated by HIF-1 alpha contribute to diverse functions including new blood vessel growth (angiogenesis), use of glucose for energy, and protection against apoptosis (programmed cell death). Preclinical data have demonstrated that PX-478 can induce apoptosis in experimental tumor models, as well as the down-regulation of factors which control angiogenesis, such as vascular endothelial growth factor (VEGF). |
| Targets: | Hypoxia-inducible factor 1-alpha |
| Inclusion Criteria: | Therapeutic strategy associated |
